BrainStorm Cell Therapeutics Showcases NurOwn at NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is excited to announce the acceptance of two important abstracts related to NurOwn® (MSC-NTF or Debamestrocel) at the upcoming Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting. As a trailblazer in cellular therapies for neurodegenerative disorders, the company is proud to share these developments.
Focus on Innovation and Impact
At this year’s NEALS conference, BrainStorm will present the latest discoveries and updates about NurOwn. Feedback and insights from the ALS community play a vital role in their mission to meet the essential needs of patients dealing with this debilitating disease. Chaim Lebovits, President and CEO of BrainStorm, highlights the company’s commitment to launching a Phase 3b clinical trial that aims to clearly demonstrate NurOwn's effectiveness in those with early-stage ALS.
Upcoming Presentations
During the conference, BrainStorm will host two informative presentations:
Title: Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program
Lead Author: Bob Dagher, MD
Session: Poster Session 1
Date and Time: 4:30 – 6:30 PM ET, Tuesday, Oct 22
Location: Sea Salon & Sand Salon, Opal Sands Resort
Title: An Overview of The Phase 3b Clinical Trial of Debamestrocel in ALS
Lead Author: Bob Dagher, MD
Session: Poster Session 2
Date and Time: 4:00 – 6:00 PM ET, Wednesday, Oct 23
Location: Sea Salon & Sand Salon, Opal Sands Resort
Near-term Milestones
As BrainStorm prepares to showcase its findings, multiple significant milestones are on the horizon, promising to elevate the impact of its research and developments in ALS treatment. These efforts reflect the company's longstanding commitment to innovating treatment solutions for ALS patients.
Exploring NurOwn's Potential
The NurOwn® platform centers on autologous MSC-NTF cells, introducing a groundbreaking therapeutic approach that zeroes in on essential pathways involved in neurodegenerative illnesses. Tailored for each ALS patient, these cells are carefully collected and designed to secrete neurotrophic factors that target the specific neural degradation caused by ALS.
Commitment to Research and Development
BrainStorm's unwavering dedication to ALS research has ushered in advancements seen in many respected peer-reviewed journals. The NurOwn clinical program has yielded essential insights into the nuances of ALS, helping to identify disease progression and inform treatment plans. The company encourages thorough analysis of their gathered data, focusing on significant biomarkers across different stages of its clinical trials, particularly during the Phase 3 analysis.
About BrainStorm Cell Therapeutics Inc.
As a leader in developing autologous adult stem cell therapies for severe neurodegenerative diseases, BrainStorm Cell Therapeutics Inc. is at the forefront of innovation. Its unique worldwide licensing agreement allows the company to develop and market the NurOwn® technology platform for creating autologous MSC-NTF cells. This technology has already received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of ALS.
Frequently Asked Questions
What are the upcoming presentations at the NEALS meeting?
BrainStorm will present two abstracts discussing the long-term benefits of Debamestrocel in ALS and an overview of the Phase 3b clinical trial.
Who is the lead author for the presentations?
Bob Dagher, MD, is the lead author for both presentations associated with NurOwn.
What is the purpose of the NurOwn technology platform?
NurOwn focuses on utilizing autologous MSC-NTF cells to develop treatments targeting neurodegenerative disease pathways, specifically in ALS.
How does BrainStorm demonstrate its commitment to ALS research?
BrainStorm supports ALS research through extensive clinical studies published in peer-reviewed journals and active participation in scientific meetings.
What is the significance of the upcoming Phase 3b trial?
The Phase 3b clinical trial aims to provide definitive evidence of NurOwn's efficacy, enhancing treatment options for early-stage ALS patients.
